Biotech Values

[DewDiligence]

4Q17 worldwide Botox sales=$864.3M, +17% YoY (+12% QoQ*):

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjcxNzR8Q2hpbGRJRD02ODc3Mjk=

• US therapeutic†: $384.0M (+4% YoY)
• US cosmetic: $228.4M (+15% YoY)
• Ex-US therapeutic: $96.9M (+11% YoY in local currency)
• Ex-US cosmetic: $155.0M (+20% YoY in local currency)

All told, 71% of Botox sales were in the US, where the therapeutic/cosmetic split was 63/37; 29% of Botox sales were ex-US, where the therapeutic/cosmetic split was 38/62.

†Includes $16.9M sales for hyperhidrosis.

*The large 4Q17 increase vs 3Q17 was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.